SDZNY OTC
Sandoz Group AG
1W: -6.5%
1M: -8.3%
3M: -2.9%
YTD: +12.1%
1Y: +35.5%
$84.08
-0.26 (-0.31%)
Weekly Expected Move ±4.8%
$74
$78
$82
$86
$90
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$35.4B
52W Range55.417-94.15
Volume858
Avg Volume26,213
Beta0.49
Dividend$1.02
Analyst Ratings
Company Info
CEORichard Saynor
Employees23,000
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2023-10-04
Websitesandoz.com
Centralbahnstrasse 4
Basel, ZG 4051
CH
Basel, ZG 4051
CH
41 61 324 11 11
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Latest News
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
Switzerland's Sandoz aims to double sales by 2035 in expanded biosimilars push
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
UTHR or SDZNY: Which Is the Better Value Stock Right Now?
Recent Insider Trades
No insider trades found